Biomedical Research Models Inc Receives 2013 Best of Springfield Award

Springfield Award Program Honors the Achievement

SPRINGFIELD September 2, 2013 – Biomedical Research Models Inc has been selected for the 2013 Best of Springfield Award in the Research Services category by the Springfield Award Program.

Each year, the Springfield Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Springfield area a great place to live, work and play.

Various sources of information were gathered and analyzed to choose the winners in each category. The 2013 Springfield Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the Springfield Award Program and data provided by third parties.

About Springfield Award Program

The Springfield Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the Springfield area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.

The Springfield Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community’s contributions to the U.S. economy.

SOURCE:
Springfield Award Program

CONTACT:
Springfield Award Program
Email: PublicRelations@awardprogram.org
URL: http://www.awardprogram.org

BioMedical Research Models Inc (BRM) awarded a $2.5 Million NIH grant.

Kejian Yang Ph.D., a research director at BioMedical Research Models Inc has been awarded a three year grant from the National Institutes of Allergy and Infectious Disease (NIAID) totaling $2,563,532. The objectives of this grant are to extend studies and develop a vaccination strategy for genital herpes. The U.S. Centers for Disease Control and Prevention (CDC) provided initial funding to develop the platform. The CDC reports that approximately 20% of the adult population in the USA is infected with Herpes Simplex Viruses type 2 (HSV-2). Infection with HSV-2 can result in significant morbidity and psychological suffering. In addition, vertical transmission of virus from mother to infant and infections in immunocompromised individuals can lead to viral encephalitis and/or dissemination of virus throughout the body. HSV-2 has also been identified as a cofactor for human immunodeficiency virus (HIV).

The development of this vaccine would clearly have an impact on the greater than $1.6 billion spent annually on direct medical costs associated with HSV-2. The U.S. Public Health Service (PHS) has recognized the significant public health issues caused by herpes simplex virus. The PHS publication, “Healthy People 2010”, has set sexually transmitted diseases as a national priority with a goal to reduce the number of adults infected with human papilloma virus and HSV-2.

Biomedical Research Models, Inc. (BRM) is a biopharmaceutical company with sites in Worcester/Springfield, MA and Baltimore, MD (Biomere LLC). BRM is dedicated to the discovery, development and commercialization of novel proprietary therapeutics. BRM has become a cash-flow positive company with active research pipelines including the 1) continued development of animal models to study autoimmune diseases, 2) identification of viruses that initiate autoimmune disease and 3) development of novel vaccine platform to combat these viruses. In addition the vaccine platform has been demonstrated to be effective for the prevention of herpes infections in animal models.

Neuralstem, Inc. announced today the execution of an exclusive license agreement to Biomedical Research Models, Inc. for the development of Neuralstem compounds

Neuralstem, Inc. announced today the execution of an exclusive license agreement to Biomedical Research Models, Inc. for the development of Neuralstem compounds to treat certain cognitive and neurological impacts of diabetes.

PRNewswire-FirstCall — Neuralstem, Inc. (OTC Bulletin Board: NRLS), headquartered here, announced today the execution of an exclusive license agreement to Biomedical Research Models, Inc. for the development of Neuralstem compounds to treat certain cognitive and neurological impacts of diabetes.

The agreement includes annual license fees until product commercialization; milestone payments upon the completion of agreed-upon clinical goals, which could total approximately $38 million for each licensed product that is approved by the FDA; as well as royalties on ensuing products.

The license covers a library of Neuralstem patent-pending compounds, discovered using Neuralstem’s patented human neural stem cells. The company said that the compounds, when orally administered, have been shown in adult mice to recruit and stimulate the body’s own stem cells to form new neurons in the brain, and may be useful in healing and protecting injured brain areas.

“What we have is a true platform technology,” said Richard Garr, Neuralstem President and Chief Executive Officer. “Neuralstem’s ability to grow regionally specific, physiologically relevant human nerve cells in large quantities, in vitro (in dishes) provides a unique tool for discovering drugs to treat neurological and psychiatric diseases. It gives the company a way to leverage our cells’ unique properties in both our cell therapy and drug development programs. Our licensee, Biomedical Research Models, Inc., is focused on developing novel drug therapies for the treatment of diabetes, and will provide an excellent partner to move the results of our drug discovery program forward in this area.”

Neuralstem recently received a $500,000 grant from the NIH to study the possible effectiveness of its compounds to treat depression. “The creation of Neuralstem’s unique drug discovery platform (patent-pending) was funded by an award from the U.S. Department of Defense several years ago,” Garr added. “Neuralstem retains the rights to these compounds for all indications other than diabetes.”

BRM signs contract with Michigan State University (MSU) to provide research services toward developing a drug treatment for Diabetic Retinopathy

BRM signs contract with Michigan State University (MSU) to provide research services toward developing a drug treatment for Diabetic Retinopathy. In January 2007, BRM signed a contract with Michigan State University (MSU) to provide research services toward developing a drug treatment for Diabetic Retinopathy. As part of the research collaboration BRM is now positioned to evaluate the MSU therapy as a possible treatment for diabetic renal failure. The University of California at San Francisco received a seven year contract totaling $220 Million. The goal of the funding is to perform clinical trials via the Immune Tolerance Network (ITN) (www.immunetolerance.org). ITN and BRM have entered into a contract with University of California at San Francisco to perform preclinical studies in autoimmunity including; Type 1 diabetes, Multiple Sclerosis and Rheumatoid Arthritis.

1 5 6 7 8